Brief: FDA Resumes E-IND Approval For Severe-To-Critical Covid-19 Patients Use Of Vyrologix Following Full Enrollment In Cytodyn's Phase 3 Trial

Cytodyn

22/12/2020 14:00

Dec 22 (Reuters) - Cytodyn Inc  CYDY.PK :
    * FDA RESUMES EIND APPROVAL FOR SEVERE-TO-CRITICAL COVID-19
PATIENTS USE OF VYROLOGIX™ (LERONLIMAB) FOLLOWING FULL
ENROLLMENT IN CYTODYN’S PHASE 3 TRIAL
    * CYTODYN INC - FDA'S DECISION WILL ENABLE CYTODYN TO
RESPOND TO
ONGOING REQUESTS FOR LERONLIMAB UNTIL PHASE 3 TRIAL DATA IS
UNBLINDED

Source text for Eikon:  ID:nGNX7stHDc 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))